logo


Summary Notice of Settlement of Bayer AG Securities Litigation
Wednesday, July 09, 2008 9:02 AM


WHITE PLAINS, N.Y., July 9 /PRNewswire/ -- The following release was issued today by Thomas M. Skelton and Richard W. Cohen of Lowey Dannenberg Cohen & Hart, P.C.:

    UNITED STATES DISTRICT COURT
    SOUTHERN DISTRICT OF NEW YORK
    In re BAYER AG SECURITIES LITIGATION
    File No. 03 CV 1546 (WHP)
    CLASS ACTION
    This Document Relates To: ALL ACTIONS.
    TO: ALL PERSONS OR ENTITIES WHO OR WHICH:

FROM AUGUST 4, 2000 THROUGH AND INCLUDING FEBRUARY 21,2003:

(A) PURCHASED OR OTHERWISE ACQUIRED ORDINARY SHARES OF BAYER AG (Ticker: BAY GR) ON THE U.S. OVER-THE-COUNTER MARKET OR PURCHASED AMERICAN DEPOSITORY RECEIPTS (ADRS) OF BAYER AG (Pink Sheets: BAYRY) ON THE NEW YORK STOCK EXCHANGE, REGARDLESS OF THE PURCHASER'S COUNTRY OF RESIDENCE AT THE TIME OF PURCHASE; OR

(B) PURCHASED OR OTHERWISE ACQUIRED ORDINARY SHARES OR ADRS OF BAYER AG ON ANY OTHER STOCK EXCHANGE AND THE PURCHASER, OR BENEFICIAL OWNER, WAS A RESIDENT OR CITIZEN OF THE UNITED STATES AT THE TIME OF PURCHASE.

This Summary Notice is given pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Southern District of New York (the 'Court') dated June 20, 2008 to advise you of a proposed settlement reached in this Class Action between Lead Plaintiff and Defendants for $18,500,000 (Eighteen Million Five Hundred Thousand Dollars) and settlement hearing in the above-captioned action.

The Second Amended Complaint in this Litigation alleged that from August 4, 2000 to August 8, 2001, Defendants publicly misrepresented the prospects for Bayer's cholesterol-lowering drug, Baycol, while failing to disclose serious health risks, which led Bayer to withdraw Baycol on August 8, 2001. The Lead Plaintiff also alleged that from August 8, 2001 to February 21, 2003, Bayer misrepresented its prior knowledge of Baycol's dangers and understated its potential liability for claims from users and purchasers of Baycol. Lead Plaintiff claimed that as a result of these alleged material misrepresentations and omissions, the market price of Bayer securities was artificially inflated during the Class Period.



(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

  
Related Press Releases
Advertisement
Popular Articles
Advertisement
Partner Center
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia